Genetic Testing Updated June 19, 2026

MCED Coverage Reality Check: Where Galleri and Multi-Cancer Screening Actually Stand With Payers

Multi-cancer early detection tests like Galleri are commercially available but largely uncovered by Medicare and commercial payers as of mid-2026. This article explains why, where FDA review and federal legislation stand, and what an established coverage pathway looks like by comparison.

A patient walks into an oncology clinic having read that a single blood draw can screen for more than fifty cancers at once. They want the Galleri test. The physician is willing. The lab can run it. And then the practical question lands on whoever manages your revenue cycle: who pays for this? For multi-cancer early detection (MCED) testing in mid-2026, the honest answer is almost always the patient, out of pocket. Understanding why that is the case, and what would have to change for it to be otherwise, is the difference between setting realistic expectations and writing off claims you never should have submitted.

Disclaimer: This is educational content, not medical, legal, or billing advice, and it is not a coverage determination for any specific patient or claim. This topic is moving quickly: FDA review timelines, federal legislation, and payer policies can change after this was written. The dates and statuses below are stated as of mid-2026 and you should verify the current FDA status, legislative status, and each payer's current policy directly before relying on any of it. Consult qualified clinical, billing, regulatory, and legal professionals before making coverage, treatment, or compliance decisions. Use this information at your own risk.

What MCED tests are, and why coverage is the hard part

Multi-cancer early detection tests look for signals shared across many cancer types, typically by analyzing circulating tumor DNA and related markers in a blood sample. Galleri, made by GRAIL, is the best-known example and the only widely available MCED test in the United States. The American Cancer Society describes these as multi-cancer detection tests that are not yet recommended for routine screening and notes that none has been approved by the FDA.

The clinical pitch is genuinely compelling. The trouble for anyone who has to get paid is that a compelling test and a covered test are two different things. Coverage decisions turn on a specific, unglamorous question that every payer asks: is there sufficient evidence that using this test changes what clinicians do and improves outcomes, enough to call it medically necessary rather than investigational? For MCED screening in asymptomatic people, payers have largely concluded the answer is "not yet." To see why, you have to look at three things at once: FDA status, the evidence base, and the structure of the Medicare benefit itself.

The FDA status: a lab-developed test, with a PMA now pending

Galleri has been on the market since 2021, but not as an FDA-approved product. It is offered as a laboratory-developed test (LDT) under CLIA regulations, the framework that lets a single high-complexity lab develop and run a test it offers as a service. That distinction matters enormously for reimbursement, because the absence of FDA approval is the first thing most payer policies cite when they decline to cover MCED testing.

That status is now in motion. On January 29, 2026, GRAIL announced it had submitted a premarket approval (PMA) application to the FDA for Galleri, completing a modular submission and supporting it with data from the PATHFINDER 2 study and the NHS-Galleri trial (GRAIL, January 2026). The FDA had previously granted Galleri Breakthrough Device designation. A PMA submission, though, is the beginning of an FDA review, not the end. As of mid-2026 the FDA had not issued a decision, and you should treat any timeline you hear as an estimate rather than a fact. This is precisely the kind of status that can change between when this was written and when you read it, so verify it directly with the FDA or GRAIL's current communications before you assume anything about approval.

The evidence question payers keep returning to

Even setting FDA status aside, commercial payers apply their own evidence standard, and MCED testing has not yet cleared it for screening use. The familiar three-part test runs through nearly every relevant medical policy: analytic validity (does the test measure what it claims, reliably), clinical validity (does the result correlate with a real clinical condition), and clinical utility (does acting on the result actually improve outcomes). MCED tests tend to show strong analytic performance and high specificity, but the clinical-utility piece, the proof that earlier detection through MCED leads to better outcomes at the population level, is the part still being established through large trials.

The professional and guideline landscape reflects that caution. The U.S. Preventive Services Task Force has grade A or B screening recommendations for only a handful of single cancers, breast, cervical, colorectal, and lung cancer in high-risk individuals, and does not currently recommend MCED screening (ASCO Educational Book, 2025). GRAIL's own PATHFINDER 2 results, presented in October 2025, were framed as showing what Galleri adds on top of USPSTF-recommended screening rather than as a replacement, reporting a more than seven-fold increase in cancers found within a year when Galleri was added to recommended screenings (GRAIL/PR Newswire, October 2025). Promising, and explicitly positioned as additive to, not a substitute for, established screening.

How that translates into payer policy

When you read the actual medical policies, the pattern is consistent. Blue Cross Blue Shield of Massachusetts classifies the use of multi-cancer early detection tests, naming Galleri, as investigational, and treats it as not a covered service (BCBS MA medical policy). Blue Shield of California maintains a comparable multicancer early detection testing policy citing the lack of FDA approval among its rationale (Blue Shield of California medical policy). "Investigational" is not a soft word in this context. It is a defined coverage status that places the test outside the medical-necessity benefit, which is why these claims are routinely denied rather than processed and paid.

The practical reality for patients shows up in price. GRAIL lists Galleri at a self-pay price, and the company itself states that insurance does not currently cover the test, while noting that certain employer programs, life insurers, and some military-affiliated channels have offered access (Galleri patient cost page). If you are setting patient expectations or designing an order-to-cash workflow around MCED, plan for self-pay and financial counseling as the baseline, not for third-party reimbursement.

The Medicare structure problem, and the bill meant to fix it

Here is the part that surprises people: even if MCED testing had a robust evidence base today, traditional Medicare would still face a structural obstacle. Medicare pays for screening tests through defined statutory benefit categories. Colorectal cancer screening, mammography, and the like each exist because Congress or CMS created a category and pathway for them. Until 2026 there was no equivalent dedicated benefit category for multi-cancer early detection screening in an asymptomatic population, and absent that category, CMS did not have a straightforward route to cover MCED screening nationally, regardless of the data.

That gap is exactly what the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act was written to close, and as of early 2026 it is law. Introduced in the 119th Congress as H.R. 842 and S. 339, it was folded into the Consolidated Appropriations Act of 2026, which the House passed on January 23, 2026, and it was signed into law on February 3, 2026 (H.R. 842, congress.gov; Rep. Sewell, House press release, February 2026). It creates a Medicare benefit category for MCED screening tests and allows CMS to begin an evidence-based coverage process, but only for tests that have received FDA approval.

Read that mechanism carefully, because it is widely misunderstood. The law does not order Medicare to cover Galleri or any other test. It builds the pathway. FDA approval still has to come first, and then CMS still has to run its own coverage process before any MCED test is paid for. So even now that the enabling law exists, this remains a multi-step sequence stretched over years: FDA approval of a specific test, then a CMS coverage determination, with the statute's coverage mechanism phased in rather than switched on at signing. Confirm the implementation timeline and any CMS rulemaking directly, since those details govern when coverage could actually begin.

A direct caution, because this is the fastest-moving corner of the topic: although the enabling law is now on the books, that is not the same as coverage, and the operative questions have simply moved downstream to FDA approval and CMS implementation. Verify the current FDA decision status and any CMS coverage rulemaking before you tell anyone that an MCED test is, or is about to be, covered. Do not let either a stale "still in committee" headline or a premature "it's the law, so it's covered" headline drive a coverage assumption.

What a settled coverage pathway looks like, by contrast

To appreciate how early MCED is, compare it to an established screening test that traveled the full road. Cologuard, the multi-target stool DNA test for colorectal cancer, is FDA-approved, is included in USPSTF colorectal screening guidance, and is covered by Medicare Part B at a defined interval for average-risk beneficiaries in the eligible age range, without cost-sharing as a preventive service (American Cancer Society, screening coverage).

Line those two tests up and the difference is not subtle. Cologuard has FDA approval, a guideline recommendation, and an existing Medicare benefit category for colorectal screening to slot into. Galleri, as of mid-2026, has a pending FDA submission, no USPSTF screening recommendation, an investigational status across major commercial policies, and a Medicare benefit category that exists only on paper, newly created by statute but unusable until an MCED test is FDA-approved and CMS acts. Every element that makes Cologuard payable is, for MCED, either in progress or not yet started. That is the whole story of why one is covered and the other generally is not.

What this means for how you operate

If you are a lab offering MCED, an oncology practice fielding patient requests, or the person who owns market access, a few things follow directly. Set patient and referrer expectations toward self-pay today; submitting MCED screening to most payers as if it were a covered benefit will generate denials and rework. Track FDA status as its own variable, because it is the gating event for almost everything downstream, including the federal legislation. And treat the Sewell Act for what it is: a newly enacted pathway to monitor, not a present-day coverage win, since no MCED test can be reimbursed under it until the FDA approves one and CMS acts.

The deeper lesson generalizes well beyond Galleri. Coverage for an emerging diagnostic is not a single fact you can learn once. It is a moving relationship among FDA status, evidence accumulation, individual payer medical policies, and statute, and each of those moves on its own clock and per test and per indication. A policy can flip from investigational to covered the quarter after an approval, or stay put for years. The operators who get paid on the right tests at the right time are the ones treating that change as something to be tracked continuously rather than rediscovered at denial. Building that monitoring discipline, whether internally or through a service like Converus that watches payer policy by test and indication, is what turns a fast-moving coverage landscape from a liability into something you can actually plan around.

For MCED specifically, the practical instruction is simple: verify the current FDA status, the current legislative status, and each payer's current policy at the moment you need to act, because all three are still in motion.

Sources

Frequently Asked Questions

Does Medicare cover Galleri or other MCED tests right now?
As of mid-2026, no. No MCED test has been approved by the FDA or established for Medicare reimbursement, so patients who get the test today generally pay out of pocket. A 2026 federal law created a Medicare benefit category for MCED screening, but coverage under it cannot begin until an MCED test is FDA-approved and CMS completes a coverage process. Verify current CMS policy before relying on this.
Why do commercial payers call MCED testing investigational?
Most commercial medical policies, including Blue Cross Blue Shield of Massachusetts and Blue Shield of California, classify multi-cancer early detection testing as investigational and not covered. The stated reasons are the lack of FDA approval and insufficient published evidence of clinical utility, meaning evidence that acting on the result improves health outcomes. Galleri has been sold since 2021 as a laboratory-developed test without FDA approval.
Has the FDA approved Galleri?
Not as of mid-2026. GRAIL announced on January 29, 2026 that it submitted a premarket approval (PMA) application to the FDA for Galleri, completing a modular submission. A regulatory decision had not been issued at the time of writing. Galleri remains a laboratory-developed test offered under CLIA. Verify the current FDA status directly.
Will the federal MCED Medicare bill change coverage soon?
Not immediately. The Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act was signed into law on February 3, 2026 as part of the Consolidated Appropriations Act of 2026, creating a Medicare benefit category for MCED screening. But the law lets CMS begin a coverage process only after an MCED test receives FDA approval, so it establishes a pathway rather than automatic coverage. As of mid-2026 no MCED test is FDA-approved, so nothing is reimbursable under it yet. Verify the current FDA and CMS status.
← Back to Knowledge Base